Perrigo Company PLC Stock TEL AVIV STOCK EXCHANGE
Equities
IE00BGH1M568
Pharmaceuticals
Sales 2024 * | 4.66B 1,771B | Sales 2025 * | 4.86B 1,849B | Capitalization | 4.23B 1,609B |
---|---|---|---|---|---|
Net income 2024 * | -51M -19.39B | Net income 2025 * | 101M 38.4B | EV / Sales 2024 * | 1.59 x |
Net Debt 2024 * | 3.18B 1,210B | Net Debt 2025 * | 3.01B 1,143B | EV / Sales 2025 * | 1.49 x |
P/E ratio 2024 * |
-83.7
x | P/E ratio 2025 * |
55.8
x | Employees | - |
Yield 2024 * |
3.53% | Yield 2025 * |
3.75% | Free-Float | 99.69% |
Latest transcript on Perrigo Company PLC
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 23-06-29 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 22-05-15 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 20-12-14 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 17-02-05 |
Bradley Alford
BRD | Director/Board Member | 67 | 17-02-05 |
1st Jan change | Capi. | |
---|---|---|
+24.17% | 562B | |
-6.44% | 358B | |
+19.26% | 322B | |
+8.21% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-11.67% | 149B | |
-6.69% | 146B |